Lisocabtagene maraleucel (BREYANZI) is the fourth chimeric antigen receptor (CAR) T cell therapy approved for certain types of non-Hodgkin lymphoma (NHL).
Read More >Umbralisib (UKONIQ, TG Therapeutics), a kinase inhibitor including PI3K-delta and casein kinase CK1-epsilon, has been approved for relapsed or refractory marginal zone lymphoma and follicular lymphoma.
Read More >
As of January 2021, there are two COVID-19 vaccines that have been approved by the Federal Drug Administration (FDA) for use in the United States
Read More >
Peripheral T-cell lymphoma (PTCL) is an aggressive (fast-growing) form of non-Hodgkin lymphoma which has typically been associated with having no standard of care. For most
Read More >U.S. Food and Drug Administration (FDA) approved the first biomarker-driven therapy for pediatric ALCL.
Read More >
Checkpoint inhibitors are a new class of drugs used by the immune system to determine whether or not to launch an immune response. By activating
Read More >
A lymphoma diagnosis can be challenging to cope with at any time, but the current pandemic has only increased stress, anxiety, and depression for many
Read More >
The emergence of biomarking testing has provided new insights into the molecular and genetic underpinnings of many types of cancer as well as differences in
Read More >
On December 11 and 18, 2020 the U.S. Food and Drug Administration (FDA) issued two COVID-19 vaccines, Pfzier BioNTech and Moderna, with emergency use authorization
Read More >
In May 2020, lymphoma-expert, Raghuveer Ranganthan, MD (Univerity of Southern California) hosted the Lymphoma Research Foundation’s Update on CAR T-Cell Therapy in Diffuse Large B-cell
Read More >
